RT Journal Article
T1 HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
A1 Bueno Muiño, Coralia
A1 Martín, Miguel
A1 Monte Millán, María del
A1 García Saénz, José Ángel
A1 López Tarruella, Sara
AB Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies.
PB MPDI
SN 2072-6694
YR 2022
FD 2022-01-20
LK https://hdl.handle.net/20.500.14352/71619
UL https://hdl.handle.net/20.500.14352/71619
LA eng
NO CIBER and Center of Biomedical Research on Cancer
DS Docta Complutense
RD 15 may 2024